X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (539) 539
index medicus (421) 421
nav1.5 voltage-gated sodium channel (381) 381
animals (308) 308
sodium channels - genetics (290) 290
mutation (246) 246
male (238) 238
cardiac & cardiovascular systems (224) 224
female (223) 223
nav1.5 voltage-gated sodium channel - genetics (187) 187
arrhythmia (177) 177
sodium channels - metabolism (161) 161
patch-clamp techniques (152) 152
electrocardiography (150) 150
muscle proteins - genetics (141) 141
long qt syndrome - genetics (136) 136
nav1.5 voltage-gated sodium channel - metabolism (134) 134
adult (121) 121
scn5a (118) 118
heart (115) 115
long-qt syndrome (113) 113
long qt syndrome (110) 110
electrophysiology (106) 106
mice (105) 105
middle aged (100) 100
cell line (94) 94
brugada-syndrome (93) 93
article (92) 92
phenotype (92) 92
physiology (91) 91
brugada syndrome - genetics (88) 88
brugada syndrome (87) 87
genetic aspects (87) 87
hek293 cells (86) 86
sodium channel blockers - pharmacology (86) 86
ion channels (85) 85
rats (85) 85
sodium channels (85) 85
pharmacology & pharmacy (84) 84
arrhythmias, cardiac - genetics (80) 80
cardiovascular (74) 74
muscle proteins - metabolism (74) 74
sodium channels - drug effects (74) 74
sodium channels - physiology (74) 74
transfection (74) 74
myocytes, cardiac - metabolism (73) 73
genetics (72) 72
nav1.5 (72) 72
analysis (71) 71
cardiac arrhythmia (66) 66
anti-arrhythmia agents - pharmacology (65) 65
genetic predisposition to disease (65) 65
st-segment elevation (63) 63
arrhythmias, cardiac - physiopathology (62) 62
sodium channel (62) 62
cells, cultured (61) 61
dose-response relationship, drug (61) 61
sodium - metabolism (61) 61
long qt syndrome - physiopathology (60) 60
sudden cardiac death (60) 60
action potentials (59) 59
arrhythmias (59) 59
expression (59) 59
myocytes, cardiac - drug effects (59) 59
na+ channel (59) 59
mutations (57) 57
action potentials - drug effects (56) 56
ion channel gating - drug effects (56) 56
genotype (55) 55
sodium (55) 55
membrane potentials - drug effects (54) 54
erg1 potassium channel (53) 53
adolescent (52) 52
risk factors (51) 51
aged (50) 50
biochemistry & molecular biology (50) 50
cardiovascular system (50) 50
conduction (49) 49
pedigree (49) 49
research (49) 49
bundle-branch block (48) 48
cardiovascular diseases (48) 48
heart diseases (47) 47
peripheral vascular disease (47) 47
cell biology (46) 46
na+ channels (46) 46
dna mutational analysis (45) 45
kinetics (45) 45
channel (43) 43
inactivation (43) 43
brugada syndrome - physiopathology (42) 42
cardiology (42) 42
multidisciplinary sciences (42) 42
myocardium - metabolism (42) 42
time factors (42) 42
mechanisms (41) 41
proteins (41) 41
sodium-channel (41) 41
channels (40) 40
medicine (40) 40
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastroenterology, ISSN 0016-5085, 06/2014, Volume 146, Issue 7, pp. 1659 - 1668
encodes the α-subunit of the voltage-gated sodium channel Na 1.5. Many patients with cardiac arrhythmias caused by mutations in also have symptoms of irritable... 
GI Motility | Voltage-Gated Sodium Channel | Genetics | Polymorphism | Constipation - genetics | Prevalence | Prospective Studies | Channelopathies - physiopathology | Channelopathies - epidemiology | Diarrhea - physiopathology | Humans | Middle Aged | Constipation - metabolism | Gastrointestinal Motility - drug effects | Diarrhea - epidemiology | Male | NAV1.5 Voltage-Gated Sodium Channel - metabolism | Channelopathies - metabolism | Mutation, Missense | Case-Control Studies | Young Adult | Channelopathies - diagnosis | Transfection | DNA Mutational Analysis | Irritable Bowel Syndrome - diagnosis | NAV1.5 Voltage-Gated Sodium Channel - drug effects | HEK293 Cells | Voltage-Gated Sodium Channel Blockers - therapeutic use | Adult | Female | Irritable Bowel Syndrome - epidemiology | NAV1.5 Voltage-Gated Sodium Channel - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Irritable Bowel Syndrome - metabolism | Risk Factors | Constipation - epidemiology | Gastrointestinal Motility - genetics | Irritable Bowel Syndrome - drug therapy | Constipation - physiopathology | Irritable Bowel Syndrome - physiopathology | Irritable Bowel Syndrome - genetics | Channelopathies - genetics | Phenotype | Channelopathies - drug therapy | Membrane Potentials | Diarrhea - genetics | Adolescent | Diarrhea - metabolism | Aged | polymorphism | genetics | GI motility | voltage-gated sodium channel | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Toxicology Letters, ISSN 0378-4274, 08/2017, Volume 277, pp. 64 - 68
Journal Article
Circulation, ISSN 0009-7322, 07/2014, Volume 130, Issue 3, pp. 224 - 234
Journal Article
Journal Article
Cardiovascular research, ISSN 0008-6363, 2017, Volume 113, Issue 7, pp. 829 - 838
Journal Article
Naunyn-Schmiedeberg's Archives of Pharmacology, ISSN 0028-1298, 10/2016, Volume 389, Issue 10, pp. 1133 - 1137
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 10/2012, Volume 126, Issue 18, pp. 2208 - 2219
Background-Heart failure is a growing cause of morbidity and mortality. Cardiac phosphatidylinositol 3-kinase signaling promotes cardiomyocyte survival and... 
heart failure | ion channels or ion channel | signal transduction | arrhythmia | LATE SODIUM CURRENT | CARDIAC & CARDIOVASCULAR SYSTEMS | PROTEIN | AKT ACTIVATION | HEART-FAILURE | LONG-QT SYNDROME | CARDIAC NA+ CHANNELS | SGK | IN-VIVO | RANOLAZINE | PERIPHERAL VASCULAR DISEASE | MODULATION | Consensus Sequence | Tachycardia, Ventricular - enzymology | Protein-Serine-Threonine Kinases - deficiency | Phosphorylation | Cardiomyopathy, Dilated - enzymology | Heart Failure - enzymology | Humans | Ranolazine | Immediate-Early Proteins - metabolism | NAV1.5 Voltage-Gated Sodium Channel - drug effects | Immediate-Early Proteins - chemistry | Acetanilides - therapeutic use | Electrocardiography | Immediate-Early Proteins - deficiency | Sodium Channel Blockers - therapeutic use | Protein-Serine-Threonine Kinases - metabolism | Disease Models, Animal | Immediate-Early Proteins - physiology | Protein-Serine-Threonine Kinases - physiology | Mice, Inbred C57BL | Protein-Serine-Threonine Kinases - genetics | Tachycardia, Ventricular - etiology | Enzyme Induction | Mice, Transgenic | Sodium Channel Blockers - pharmacology | Piperazines - therapeutic use | NAV1.5 Voltage-Gated Sodium Channel - physiology | Ventricular Remodeling - physiology | Protein Interaction Mapping | Cardiomegaly, Exercise-Induced | Animals | Immediate-Early Proteins - genetics | Hypertension - complications | Phosphatidylinositol 3-Kinases - physiology | Mice | Protein Processing, Post-Translational | Protein-Serine-Threonine Kinases - chemistry | NAV1.5 Voltage-Gated Sodium Channel - chemistry | Ion Channel Gating - drug effects | Heart failure | Care and treatment | Prognosis | Physiological aspects | Serum | Cellular signal transduction | Research | Phosphotransferases
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 08/2017, Volume 329, pp. 309 - 317
Retigabine, currently used as antiepileptic drug, has a wide range of potential medical uses. Administration of the drug in patients can lead to QT interval... 
Cardiac arrhythmia | QT interval | Cardiomyocytes | Ion channels | Retigabine | Sympathetic ganglionic neurons | PHARMACOKINETIC INTERACTION | HEALTHY-SUBJECTS | CARDIAC-ARRHYTHMIAS | EZOGABINE RETIGABINE | PARTIAL-ONSET SEIZURES | PARTIAL EPILEPSY | TORSADE-DE-POINTES | PHARMACOLOGY & PHARMACY | RAT SYMPATHETIC NEURONS | TOXICOLOGY | CHANNEL OPENERS | Ganglionic Blockers - toxicity | Arrhythmias, Cardiac - chemically induced | Humans | Ion Channels - genetics | NAV1.5 Voltage-Gated Sodium Channel - metabolism | Arrhythmias, Cardiac - physiopathology | Dose-Response Relationship, Drug | Heart Rate - drug effects | Transfection | Time Factors | NAV1.5 Voltage-Gated Sodium Channel - drug effects | Voltage-Gated Sodium Channel Blockers - toxicity | Potassium Channel Blockers - toxicity | Action Potentials - drug effects | Induced Pluripotent Stem Cells - metabolism | Arrhythmias, Cardiac - metabolism | Cell Line | Guinea Pigs | Heart Conduction System - metabolism | Induced Pluripotent Stem Cells - drug effects | Risk Assessment | Isolated Heart Preparation | Ganglia, Sympathetic - metabolism | Heart Conduction System - drug effects | ERG1 Potassium Channel - metabolism | Rats, Sprague-Dawley | Anticonvulsants - toxicity | Ion Channels - antagonists & inhibitors | Calcium Channel Blockers - toxicity | Animals | Ganglia, Sympathetic - physiopathology | Myocytes, Cardiac - drug effects | Norepinephrine - metabolism | Heart Conduction System - physiopathology | Ion Channels - metabolism | Phenylenediamines - toxicity | Calcium Channels, L-Type - drug effects | Myocytes, Cardiac - metabolism | Calcium Channels, L-Type - metabolism | ERG1 Potassium Channel - antagonists & inhibitors | Ganglia, Sympathetic - drug effects | Carbamates - toxicity | Heart | Anticonvulsants | Calcium channels | Arrhythmia | Electrocardiogram | Stem cells | Electrocardiography | Noradrenaline | Electric properties | Analysis | Neurophysiology | Index Medicus | ECOLOGICAL CONCENTRATION | GUINEA PIGS | ELECTRICAL PROPERTIES | IONS | POTENTIALS | 60 APPLIED LIFE SCIENCES | CONCENTRATION RATIO | HEART | INHIBITION | ANTICONVULSANTS | STEM CELLS | AUTONOMIC NERVOUS SYSTEM | MODULATION | NERVE CELLS
Journal Article